Summary

The global Point-of-Care Molecular Diagnostic Cartridges market is projected to grow from US$ 2820 million in 2025 to US$ 4910 million by 2032, at a CAGR of 8.2% (2026-2032), driven by critical product segments and diverse end‑use applications.
Point-of-Care Molecular Diagnostic Cartridges are single-use in vitro diagnostic consumables designed to operate with dedicated near-patient molecular testing instruments and integrate molecular assay reagents with cartridge, cassette, pouch, tube, chip or equivalent disposable structures. The products primarily use PCR-based or isothermal nucleic acid amplification technologies and may integrate specimen pretreatment, nucleic acid extraction, purification, amplification, signal detection and result generation into a closed workflow. Commercial configurations include fully integrated cartridges that complete most sample-to-answer processes in one disposable unit and split consumable systems that separate extraction and amplification into dedicated components. Individual assays may provide single-analyte detection or multiplex detection of multiple clinically relevant targets. Point-of-Care Molecular Diagnostic Cartridges are mainly used for rapid diagnosis of respiratory infections, tuberculosis, sexually transmitted infections, vaginal infections, perinatal infections and blood-borne viral infections, as well as selected pharmacogenomic applications. Their core value lies in transferring high-sensitivity molecular testing from centralized laboratories toward emergency departments, outpatient clinics, decentralized diagnostic facilities, primary care settings and other near-patient environments while retaining standardized, closed and instrument-controlled testing workflows.
Key Findings
PCR based cartridges remain the dominant product type while isothermal amplification is expanding in rapid and low complexity testing
Respiratory infection testing remains one of the largest application clusters while tuberculosis and decentralized STI testing offer substantial incremental demand
Market Trends
The Point-of-Care Molecular Diagnostic Cartridges industry is moving toward shorter turnaround times, deeper workflow integration and broader multiplex menus. Fully enclosed sample-to-answer designs are increasingly used to reduce manual transfer steps and contamination risk, while lyophilized reagents, microfluidic fluid handling and automated assay interpretation support operation outside conventional molecular laboratories. At the same time, platform developers are expanding from single-pathogen assays toward respiratory panels, sexually transmitted infection panels and other syndromic applications, allowing installed instruments to generate a wider recurring consumables base. Rapid PCR remains central to the market, but isothermal amplification platforms are strengthening their position where simplified operation, compact instrumentation and very short response times are prioritized. Another structural trend is the extension of molecular POCT beyond respiratory testing toward tuberculosis, hepatitis, HCV confirmation, women’s health and pharmacogenomic decision support. Commercial adoption is increasingly linked to the ability to deliver actionable results during the same patient encounter rather than simply replacing conventional laboratory PCR with a smaller instrument. bioMérieux reported that SPOTFIRE test volumes more than doubled in 2025 while its installed base reached 6,400 instruments, illustrating the continued expansion of decentralized multiplex molecular testing.
Market Dynamics
Drivers
Growth in Point-of-Care Molecular Diagnostic Cartridges is supported by the clinical need to shorten the interval between specimen collection, diagnosis and treatment. Respiratory infections create substantial recurring testing demand in emergency, urgent-care and outpatient settings, while tuberculosis programs are driving deployment of molecular tests closer to patients in countries where centralized laboratory access remains limited. WHO reported that only 54% of people newly diagnosed with tuberculosis in 2024 had initially been tested with a WHO-recommended rapid diagnostic test, compared with a target of universal initial rapid testing by 2027, leaving significant room for decentralized molecular testing expansion. The installed-base business model also reinforces cartridge demand because each analyzer placement creates recurring consumption of proprietary tests. Expanding menus for STI diagnosis, HCV confirmation, women’s health and pharmacogenomics further improve instrument utilization and reduce dependence on a single seasonal application.
Restraints
Market expansion remains constrained by the cost differential between cartridge-based molecular testing and centralized high-throughput PCR, particularly in routine testing environments where turnaround time is less critical. Proprietary analyzer-cartridge architectures also lock customers into platform-specific consumables, which can limit adoption when assay menus are narrow or annual testing volumes are insufficient to justify instrument placement. Reimbursement conditions vary by country and clinical setting, while respiratory assay utilization can fluctuate substantially with seasonal infection intensity. Manufacturers must also maintain stringent lot-to-lot reagent consistency, closed-fluidic reliability and instrument-cartridge compatibility, making quality control and manufacturing validation more demanding than for conventional reagent kits. In price-sensitive public-health markets, competitive procurement places continuing pressure on cartridge ASP, while healthcare systems may favor laboratory consolidation when centralized facilities can provide adequate turnaround and lower unit cost.
Opportunities
The largest incremental opportunities are concentrated in applications where molecular accuracy is clinically valuable but access to conventional PCR laboratories remains insufficient. Tuberculosis represents a major opportunity in primary and decentralized care, particularly across high-burden countries in Asia and Africa. Molbio has deployed more than 10,000 Truenat devices and exports its platform to more than 85 countries, demonstrating that portable molecular systems can scale beyond specialist laboratories. STI testing also offers attractive same-visit applications because rapid CT, NG and other pathogen results can support immediate treatment decisions and reduce loss to follow-up. Additional opportunities are developing in HCV RNA confirmation, maternal and perinatal testing, pharmacogenomic guidance and emerging infectious disease response. Product platforms able to add assays without fundamentally changing installed hardware can capture greater lifetime cartridge consumption and improve the economics of decentralized molecular testing.
Challenges
The industry faces a persistent balance between molecular-test performance, assay complexity, turnaround time and cost. Multiplex cartridges require more complex primer and probe design, fluid control, reaction optimization and interpretation algorithms, which can increase development time and regulatory burden. Commercial success also depends on achieving sufficient instrument placement because low installed utilization can weaken cartridge economics even when assay performance is strong. Expansion into lower-income markets requires pricing that supports broad public-health procurement while preserving sustainable manufacturing margins. Regulatory fragmentation across the United States, Europe, China and other markets can delay synchronized global launches, and assay-menu differences between jurisdictions may reduce manufacturing scale efficiencies. Supply continuity for enzymes, oligonucleotides, specialty plastics and other diagnostic-grade inputs remains important because cartridge platforms depend on tightly controlled materials and reproducible automated assembly.
Industry Chain Analysis
The upstream segment of the Point-of-Care Molecular Diagnostic Cartridges industry consists primarily of molecular biology reagents, primers and probes, enzymes, lyophilization materials, diagnostic-grade polymers, microfluidic components, electronic and optical components for associated analyzers, and automated manufacturing equipment. Value creation increasingly depends on the interaction between reagent chemistry and cartridge engineering rather than on either element alone. Fluidic architecture must reliably control extraction, reaction transfer and amplification conditions, while reagent formulation must remain stable through production, logistics and storage. Suppliers capable of supporting diagnostic-grade consistency and high-volume automation therefore play a critical role in scaling commercial platforms.
The midstream segment covers assay development, cartridge design, instrument development, automated filling and sealing, assembly, quality control, regulatory registration and commercial manufacturing. Recurring value is concentrated in disposable tests after instruments are installed, making cartridge utilization a critical commercial metric. Molbio disclosed installed annual capacity of 39 million Truenat test kits as of March 2025, with substantial unused capacity available for further growth, illustrating the scale required by established decentralized molecular platforms. Downstream demand comes from emergency departments, outpatient clinics, decentralized hospital laboratories, primary-care facilities, infectious-disease programs and other near-patient settings where faster molecular results can affect clinical decisions during the same encounter.
Segment Insights
By product type, PCR Molecular Diagnostic Cartridges remain the principal technology segment because real-time PCR is well established clinically, supports both single-analyte and multiplex testing and is used across major platforms for respiratory disease, tuberculosis, STI and other infectious-disease applications. Isothermal Amplification Molecular Diagnostic Cartridges form a smaller but strategically important segment, particularly in compact systems designed for simplified workflows and short turnaround times. The competitive distinction is increasingly based not only on amplification chemistry but also on how effectively the disposable integrates sample preparation, reaction control and result interpretation.
By consumable architecture, Fully Integrated Cartridges generally provide the strongest sample-to-answer workflow and are particularly suited to decentralized environments where operator intervention must be minimized. Split Consumable Systems remain commercially relevant where separate extraction and amplification components can reduce manufacturing cost or provide greater platform flexibility. In analyte structure, Single Analyte Cartridges continue to serve high-volume targeted applications, while Multiplex Cartridges are gaining importance in respiratory and syndromic testing because one patient presentation may correspond to several pathogens with similar symptoms. Multiplexing can increase clinical information per test, although higher assay complexity generally raises cartridge design and validation requirements.
Downstream Market Opportunities
Downstream opportunity is shifting from broad institutional adoption toward highly specific clinical workflows. In emergency and urgent-care respiratory testing, molecular cartridges can distinguish influenza, SARS-CoV-2, RSV and other pathogens during the patient encounter and support faster isolation or treatment decisions. In tuberculosis, portable systems can extend molecular diagnosis to district hospitals and primary diagnostic sites that lack full laboratory infrastructure; WHO data show that rapid molecular testing coverage remains materially below universal access in many high-burden countries. In sexual-health services, same-visit molecular testing for CT, NG and related pathogens can reduce delayed treatment and patient loss to follow-up. Additional high-value use cases include intrapartum GBS assessment, HCV RNA confirmation and rapid pharmacogenomic testing before antiplatelet or antibiotic therapy. These applications favor platforms that combine short turnaround, simple operation and broad assay menus rather than instruments optimized for a single episodic disease.
Regional Insights
North America remains the most developed high-value regional market for Point-of-Care Molecular Diagnostic Cartridges, supported by a large installed base of molecular POCT instruments, extensive use of rapid respiratory testing and a regulatory pathway that allows selected tests to obtain CLIA-waived status for decentralized operation. The region also contains a high concentration of established and emerging manufacturers, supporting frequent product launches and menu expansion. Europe has a similarly advanced clinical environment but displays greater variation in procurement models and decentralized testing practices across countries; Germany, France, Italy, Belgium and the United Kingdom are notable centers of product development and manufacturing.
Asia-Pacific represents the strongest incremental volume opportunity. China has built a broad domestic molecular-diagnostics manufacturing base, while South Korea and Japan support established cartridge platforms and specialized near-patient products. India is particularly important for decentralized infectious-disease testing because portable PCR is being deployed at scale for tuberculosis and other public-health applications. Molbio reports exports to more than 85 countries, illustrating the growing role of India-based platforms in emerging markets. Southeast Asia also offers expansion potential through infectious-disease programs and decentralized diagnostic networks. Africa is primarily a demand-side opportunity rather than a major manufacturing cluster, with tuberculosis and other communicable-disease programs creating long-term need for affordable, portable molecular testing.
Competitive Landscape Analysis
The verified core competitive landscape comprises 27 manufacturers and combines multinational diagnostics groups with regional molecular-POCT specialists. Large established participants such as Cepheid, Roche Molecular Systems, BioFire Diagnostics, Abbott Diagnostics Scarborough, DiaSorin Molecular and Bosch Healthcare Solutions compete through extensive regulatory experience, installed instrument bases, assay development capabilities and established clinical channels. SD BIOSENSOR has strengthened the Asian molecular POCT position through the STANDARD M10 platform, while Molbio Diagnostics has developed a differentiated model centered on portable PCR and high-volume deployment in decentralized and public-health environments. Chinese manufacturers including Wondfo, Sansure Biotech, Coyote Bioscience, Ustar Biotechnologies, Xi’an Tianlong and other confirmed producers increasingly compete on integrated cartridge design, domestic manufacturing and expanding assay menus. The market is therefore not characterized by a single competitive model: global groups emphasize installed-base scale and broad clinical access, regional producers emphasize cost, portability and localized menus, while smaller specialists compete in multiplex respiratory testing, pharmacogenomics and other focused applications. Competitive advantage increasingly depends on the combination of assay breadth, cartridge manufacturing scale, regulatory reach, analyzer utilization and recurring test economics rather than instrument performance alone.
Report Scope
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Point-of-Care Molecular Diagnostic Cartridges market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.
Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers (sales volume, revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Cepheid
Roche Molecular Systems, Inc.
BioFire Diagnostics, LLC
Abbott Diagnostics Scarborough, Inc.
LEX Diagnostics Limited
DiaSorin Molecular LLC
Bosch Healthcare Solutions GmbH
SD BIOSENSOR, Inc.
Guangzhou Wondfo Biotech Co., Ltd.
Sansure Biotech Inc.
Molbio Diagnostics Limited
MIZUHO MEDY Co., Ltd.
Coyote Bioscience Co., Ltd.
Rocgene Beijing Scientific Instruments Co., Ltd.
Credo Diagnostics Biomedical Pte. Ltd.
miDiagnostics NV
GeneReach Biotechnology Corp.
Ustar Biotechnologies Hangzhou Ltd.
BIONEER CORPORATION
Diagnostics for the Real World Ltd.
Xi'an Tianlong Science and Technology Co., Ltd.
Baebies, Inc.
Autonomous Medical Devices Incorporated
Nuclein, LLC
Genedrive Diagnostics Ltd
Igenesis Shanghai Co., Ltd.
Guangzhou Pluslife Biotech Co., Ltd.
Segment by Type
PCR Molecular Diagnostic Cartridge
Isothermal Amplification Molecular Diagnostic Cartridge
Other
Segment by Analyte Multiplexing Level
Single Analyte Cartridge
Multiplex Cartridge
Other
Segment by Application
Respiratory Infection Diagnosis
Tuberculosis Diagnosis
Sexually Transmitted Infection Diagnosis
Vaginal Infection Diagnosis
Maternal Perinatal Infection Screening
Blood Borne Viral Infection Diagnosis
Pharmacogenomic Therapy Guidance
Other
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
Europe
Germany
France
U.K.
Italy
Russia
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Point-of-Care Molecular Diagnostic Cartridges study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape: ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down sales and revenue by Application and country, profiles key manufacturers and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional sales, revenue and market by Application and manufacturers, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies sales and revenue by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures sales and revenue by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates sales and revenue by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth: details product specs, sales, revenue, margins; top manufactures 2025 sales breakdowns by product type, by Application, by sales region SWOT analysis, and recent strategic developments
Chapter 12: Supply chain: analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る

Table of Contents

1 Study Coverage
1.1 Introduction to Point-of-Care Molecular Diagnostic Cartridges: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Point-of-Care Molecular Diagnostic Cartridges Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 PCR Molecular Diagnostic Cartridge
1.2.3 Isothermal Amplification Molecular Diagnostic Cartridge
1.2.4 Other
1.3 Market Segmentation by Analyte Multiplexing Level
1.3.1 Global Point-of-Care Molecular Diagnostic Cartridges Market Size by Analyte Multiplexing Level, 2021 vs 2025 vs 2032
1.3.2 Single Analyte Cartridge
1.3.3 Multiplex Cartridge
1.3.4 Other
1.4 Market Segmentation by Application
1.4.1 Global Point-of-Care Molecular Diagnostic Cartridges Market Size by Application, 2021 vs 2025 vs 2032
1.4.2 Respiratory Infection Diagnosis
1.4.3 Tuberculosis Diagnosis
1.4.4 Sexually Transmitted Infection Diagnosis
1.4.5 Vaginal Infection Diagnosis
1.4.6 Maternal Perinatal Infection Screening
1.4.7 Blood Borne Viral Infection Diagnosis
1.4.8 Pharmacogenomic Therapy Guidance
1.4.9 Other
1.5 Assumptions and Limitations
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Point-of-Care Molecular Diagnostic Cartridges Revenue Estimates and Forecasts (2021-2032)
2.2 Global Point-of-Care Molecular Diagnostic Cartridges Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.3 Global Point-of-Care Molecular Diagnostic Cartridges Sales Estimates and Forecasts (2021-2032)
2.4 Global Point-of-Care Molecular Diagnostic Cartridges Sales by Region
2.4.1 Sales Comparison: 2021 vs 2025 vs 2032
2.4.2 Historical and Forecasted Sales by Region (2021-2032)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2021-2032)

3 Competitive Landscape
3.1 Global Point-of-Care Molecular Diagnostic Cartridges Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2021-2026)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2025)
3.2 Global Point-of-Care Molecular Diagnostic Cartridges Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2021-2026)
3.2.2 Global Key Manufacturer Revenue Ranking (2024 vs. 2025)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2021 vs 2025)
3.3.2 Manufacturer-Level Price Trends (2021-2026)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Key Manufacturers Market Share by Product Type
3.5.1 PCR Molecular Diagnostic Cartridge: Market Share by Key Manufacturers
3.5.2 Isothermal Amplification Molecular Diagnostic Cartridge: Market Share by Key Manufacturers
3.5.3 Other: Market Share by Key Manufacturers
3.6 Global Point-of-Care Molecular Diagnostic Cartridges Market Concentration and Dynamics
3.6.1 Global Market Concentration
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment

4 Product Segmentation
4.1 Global Point-of-Care Molecular Diagnostic Cartridges Sales Performance by Type
4.1.1 Global Point-of-Care Molecular Diagnostic Cartridges Sales Volume by Type (2021-2032)
4.1.2 Global Point-of-Care Molecular Diagnostic Cartridges Revenue by Type (2021-2032)
4.1.3 Global Average Selling Price (ASP) Trends by Type (2021-2032)
4.2 Global Point-of-Care Molecular Diagnostic Cartridges Sales Performance by Analyte Multiplexing Level
4.2.1 Global Point-of-Care Molecular Diagnostic Cartridges Sales Volume by Analyte Multiplexing Level (2021-2032)
4.2.2 Global Point-of-Care Molecular Diagnostic Cartridges Revenue by Analyte Multiplexing Level (2021-2032)
4.2.3 Global Average Selling Price (ASP) Trends by Analyte Multiplexing Level (2021-2032)
4.3 Product Technology Differentiation
4.4 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.4.1 High-Growth Niches and Adoption Drivers
4.4.2 Profitability Hotspots and Cost Drivers
4.4.3 Substitution Threats

5 Downstream Applications and Customers
5.1 Global Point-of-Care Molecular Diagnostic Cartridges Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2021-2032)
5.1.2 Global Sales Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Point-of-Care Molecular Diagnostic Cartridges Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.2.2 Revenue-Based Market Share by Application (2021-2032)
5.3 Global Pricing Dynamics by Application (2021-2032)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application

6 North America
6.1 North America Sales Volume and Revenue (2021-2032)
6.2 North America Key Manufacturers Sales Revenue in 2025
6.3 North America Point-of-Care Molecular Diagnostic Cartridges Sales and Revenue by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Point-of-Care Molecular Diagnostic Cartridges Market Size by Country
6.5.1 North America Revenue by Country
6.5.2 North America Sales Trends by Country
6.5.3 US
6.5.4 Canada
6.5.5 Mexico

7 Europe
7.1 Europe Sales Volume and Revenue (2021-2032)
7.2 Europe Key Manufacturers Sales Revenue in 2025
7.3 Europe Point-of-Care Molecular Diagnostic Cartridges Sales and Revenue by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Point-of-Care Molecular Diagnostic Cartridges Market Size by Country
7.5.1 Europe Revenue by Country
7.5.2 Europe Sales Trends by Country
7.5.3 Germany
7.5.4 France
7.5.5 U.K.
7.5.6 Italy
7.5.7 Russia

8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2021-2032)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2025
8.3 Asia-Pacific Point-of-Care Molecular Diagnostic Cartridges Sales and Revenue by Application (2021-2032)
8.4 Asia-Pacific Point-of-Care Molecular Diagnostic Cartridges Market Size by Region
8.4.1 Asia-Pacific Revenue by Region
8.4.2 Asia-Pacific Sales Trends by Region
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Southeast Asia
8.6.1 Southeast Asia Revenue by Country (2021 vs 2025 vs 2032)
8.6.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.7 China
8.8 Japan
8.9 South Korea
8.10 China Taiwan
8.11 India

9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2021-2032)
9.2 Central and South America Key Manufacturers Sales Revenue in 2025
9.3 Central and South America Point-of-Care Molecular Diagnostic Cartridges Sales and Revenue by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Point-of-Care Molecular Diagnostic Cartridges Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2021-2032)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2025
10.3 Middle East and Africa Point-of-Care Molecular Diagnostic Cartridges Sales and Revenue by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Point-of-Care Molecular Diagnostic Cartridges Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Turkey
10.5.4 Egypt
10.5.5 South Africa

11 Corporate Profile
11.1 Cepheid
11.1.1 Cepheid Corporation Information
11.1.2 Cepheid Business Overview
11.1.3 Cepheid Point-of-Care Molecular Diagnostic Cartridges Product Models, Descriptions and Specifications
11.1.4 Cepheid Point-of-Care Molecular Diagnostic Cartridges Sales, Price, Revenue and Gross Margin (2021-2026)
11.1.5 Cepheid Point-of-Care Molecular Diagnostic Cartridges Sales by Product in 2025
11.1.6 Cepheid Point-of-Care Molecular Diagnostic Cartridges Sales by Application in 2025
11.1.7 Cepheid Point-of-Care Molecular Diagnostic Cartridges Sales by Geographic Area in 2025
11.1.8 Cepheid Point-of-Care Molecular Diagnostic Cartridges SWOT Analysis
11.1.9 Cepheid Recent Developments
11.2 Roche Molecular Systems, Inc.
11.2.1 Roche Molecular Systems, Inc. Corporation Information
11.2.2 Roche Molecular Systems, Inc. Business Overview
11.2.3 Roche Molecular Systems, Inc. Point-of-Care Molecular Diagnostic Cartridges Product Models, Descriptions and Specifications
11.2.4 Roche Molecular Systems, Inc. Point-of-Care Molecular Diagnostic Cartridges Sales, Price, Revenue and Gross Margin (2021-2026)
11.2.5 Roche Molecular Systems, Inc. Point-of-Care Molecular Diagnostic Cartridges Sales by Product in 2025
11.2.6 Roche Molecular Systems, Inc. Point-of-Care Molecular Diagnostic Cartridges Sales by Application in 2025
11.2.7 Roche Molecular Systems, Inc. Point-of-Care Molecular Diagnostic Cartridges Sales by Geographic Area in 2025
11.2.8 Roche Molecular Systems, Inc. Point-of-Care Molecular Diagnostic Cartridges SWOT Analysis
11.2.9 Roche Molecular Systems, Inc. Recent Developments
11.3 BioFire Diagnostics, LLC
11.3.1 BioFire Diagnostics, LLC Corporation Information
11.3.2 BioFire Diagnostics, LLC Business Overview
11.3.3 BioFire Diagnostics, LLC Point-of-Care Molecular Diagnostic Cartridges Product Models, Descriptions and Specifications
11.3.4 BioFire Diagnostics, LLC Point-of-Care Molecular Diagnostic Cartridges Sales, Price, Revenue and Gross Margin (2021-2026)
11.3.5 BioFire Diagnostics, LLC Point-of-Care Molecular Diagnostic Cartridges Sales by Product in 2025
11.3.6 BioFire Diagnostics, LLC Point-of-Care Molecular Diagnostic Cartridges Sales by Application in 2025
11.3.7 BioFire Diagnostics, LLC Point-of-Care Molecular Diagnostic Cartridges Sales by Geographic Area in 2025
11.3.8 BioFire Diagnostics, LLC Point-of-Care Molecular Diagnostic Cartridges SWOT Analysis
11.3.9 BioFire Diagnostics, LLC Recent Developments
11.4 Abbott Diagnostics Scarborough, Inc.
11.4.1 Abbott Diagnostics Scarborough, Inc. Corporation Information
11.4.2 Abbott Diagnostics Scarborough, Inc. Business Overview
11.4.3 Abbott Diagnostics Scarborough, Inc. Point-of-Care Molecular Diagnostic Cartridges Product Models, Descriptions and Specifications
11.4.4 Abbott Diagnostics Scarborough, Inc. Point-of-Care Molecular Diagnostic Cartridges Sales, Price, Revenue and Gross Margin (2021-2026)
11.4.5 Abbott Diagnostics Scarborough, Inc. Point-of-Care Molecular Diagnostic Cartridges Sales by Product in 2025
11.4.6 Abbott Diagnostics Scarborough, Inc. Point-of-Care Molecular Diagnostic Cartridges Sales by Application in 2025
11.4.7 Abbott Diagnostics Scarborough, Inc. Point-of-Care Molecular Diagnostic Cartridges Sales by Geographic Area in 2025
11.4.8 Abbott Diagnostics Scarborough, Inc. Point-of-Care Molecular Diagnostic Cartridges SWOT Analysis
11.4.9 Abbott Diagnostics Scarborough, Inc. Recent Developments
11.5 LEX Diagnostics Limited
11.5.1 LEX Diagnostics Limited Corporation Information
11.5.2 LEX Diagnostics Limited Business Overview
11.5.3 LEX Diagnostics Limited Point-of-Care Molecular Diagnostic Cartridges Product Models, Descriptions and Specifications
11.5.4 LEX Diagnostics Limited Point-of-Care Molecular Diagnostic Cartridges Sales, Price, Revenue and Gross Margin (2021-2026)
11.5.5 LEX Diagnostics Limited Point-of-Care Molecular Diagnostic Cartridges Sales by Product in 2025
11.5.6 LEX Diagnostics Limited Point-of-Care Molecular Diagnostic Cartridges Sales by Application in 2025
11.5.7 LEX Diagnostics Limited Point-of-Care Molecular Diagnostic Cartridges Sales by Geographic Area in 2025
11.5.8 LEX Diagnostics Limited Point-of-Care Molecular Diagnostic Cartridges SWOT Analysis
11.5.9 LEX Diagnostics Limited Recent Developments
11.6 DiaSorin Molecular LLC
11.6.1 DiaSorin Molecular LLC Corporation Information
11.6.2 DiaSorin Molecular LLC Business Overview
11.6.3 DiaSorin Molecular LLC Point-of-Care Molecular Diagnostic Cartridges Product Models, Descriptions and Specifications
11.6.4 DiaSorin Molecular LLC Point-of-Care Molecular Diagnostic Cartridges Sales, Price, Revenue and Gross Margin (2021-2026)
11.6.5 DiaSorin Molecular LLC Recent Developments
11.7 Bosch Healthcare Solutions GmbH
11.7.1 Bosch Healthcare Solutions GmbH Corporation Information
11.7.2 Bosch Healthcare Solutions GmbH Business Overview
11.7.3 Bosch Healthcare Solutions GmbH Point-of-Care Molecular Diagnostic Cartridges Product Models, Descriptions and Specifications
11.7.4 Bosch Healthcare Solutions GmbH Point-of-Care Molecular Diagnostic Cartridges Sales, Price, Revenue and Gross Margin (2021-2026)
11.7.5 Bosch Healthcare Solutions GmbH Recent Developments
11.8 SD BIOSENSOR, Inc.
11.8.1 SD BIOSENSOR, Inc. Corporation Information
11.8.2 SD BIOSENSOR, Inc. Business Overview
11.8.3 SD BIOSENSOR, Inc. Point-of-Care Molecular Diagnostic Cartridges Product Models, Descriptions and Specifications
11.8.4 SD BIOSENSOR, Inc. Point-of-Care Molecular Diagnostic Cartridges Sales, Price, Revenue and Gross Margin (2021-2026)
11.8.5 SD BIOSENSOR, Inc. Recent Developments
11.9 Guangzhou Wondfo Biotech Co., Ltd.
11.9.1 Guangzhou Wondfo Biotech Co., Ltd. Corporation Information
11.9.2 Guangzhou Wondfo Biotech Co., Ltd. Business Overview
11.9.3 Guangzhou Wondfo Biotech Co., Ltd. Point-of-Care Molecular Diagnostic Cartridges Product Models, Descriptions and Specifications
11.9.4 Guangzhou Wondfo Biotech Co., Ltd. Point-of-Care Molecular Diagnostic Cartridges Sales, Price, Revenue and Gross Margin (2021-2026)
11.9.5 Guangzhou Wondfo Biotech Co., Ltd. Recent Developments
11.10 Sansure Biotech Inc.
11.10.1 Sansure Biotech Inc. Corporation Information
11.10.2 Sansure Biotech Inc. Business Overview
11.10.3 Sansure Biotech Inc. Point-of-Care Molecular Diagnostic Cartridges Product Models, Descriptions and Specifications
11.10.4 Sansure Biotech Inc. Point-of-Care Molecular Diagnostic Cartridges Sales, Price, Revenue and Gross Margin (2021-2026)
11.10.5 Sansure Biotech Inc. Recent Developments
11.11 Molbio Diagnostics Limited
11.11.1 Molbio Diagnostics Limited Corporation Information
11.11.2 Molbio Diagnostics Limited Business Overview
11.11.3 Molbio Diagnostics Limited Point-of-Care Molecular Diagnostic Cartridges Product Models, Descriptions and Specifications
11.11.4 Molbio Diagnostics Limited Point-of-Care Molecular Diagnostic Cartridges Sales, Price, Revenue and Gross Margin (2021-2026)
11.11.5 Molbio Diagnostics Limited Recent Developments
11.12 MIZUHO MEDY Co., Ltd.
11.12.1 MIZUHO MEDY Co., Ltd. Corporation Information
11.12.2 MIZUHO MEDY Co., Ltd. Business Overview
11.12.3 MIZUHO MEDY Co., Ltd. Point-of-Care Molecular Diagnostic Cartridges Product Models, Descriptions and Specifications
11.12.4 MIZUHO MEDY Co., Ltd. Point-of-Care Molecular Diagnostic Cartridges Sales, Price, Revenue and Gross Margin (2021-2026)
11.12.5 MIZUHO MEDY Co., Ltd. Recent Developments
11.13 Coyote Bioscience Co., Ltd.
11.13.1 Coyote Bioscience Co., Ltd. Corporation Information
11.13.2 Coyote Bioscience Co., Ltd. Business Overview
11.13.3 Coyote Bioscience Co., Ltd. Point-of-Care Molecular Diagnostic Cartridges Product Models, Descriptions and Specifications
11.13.4 Coyote Bioscience Co., Ltd. Point-of-Care Molecular Diagnostic Cartridges Sales, Price, Revenue and Gross Margin (2021-2026)
11.13.5 Coyote Bioscience Co., Ltd. Recent Developments
11.14 Rocgene Beijing Scientific Instruments Co., Ltd.
11.14.1 Rocgene Beijing Scientific Instruments Co., Ltd. Corporation Information
11.14.2 Rocgene Beijing Scientific Instruments Co., Ltd. Business Overview
11.14.3 Rocgene Beijing Scientific Instruments Co., Ltd. Point-of-Care Molecular Diagnostic Cartridges Product Models, Descriptions and Specifications
11.14.4 Rocgene Beijing Scientific Instruments Co., Ltd. Point-of-Care Molecular Diagnostic Cartridges Sales, Price, Revenue and Gross Margin (2021-2026)
11.14.5 Rocgene Beijing Scientific Instruments Co., Ltd. Recent Developments
11.15 Credo Diagnostics Biomedical Pte. Ltd.
11.15.1 Credo Diagnostics Biomedical Pte. Ltd. Corporation Information
11.15.2 Credo Diagnostics Biomedical Pte. Ltd. Business Overview
11.15.3 Credo Diagnostics Biomedical Pte. Ltd. Point-of-Care Molecular Diagnostic Cartridges Product Models, Descriptions and Specifications
11.15.4 Credo Diagnostics Biomedical Pte. Ltd. Point-of-Care Molecular Diagnostic Cartridges Sales, Price, Revenue and Gross Margin (2021-2026)
11.15.5 Credo Diagnostics Biomedical Pte. Ltd. Recent Developments
11.16 miDiagnostics NV
11.16.1 miDiagnostics NV Corporation Information
11.16.2 miDiagnostics NV Business Overview
11.16.3 miDiagnostics NV Point-of-Care Molecular Diagnostic Cartridges Product Models, Descriptions and Specifications
11.16.4 miDiagnostics NV Point-of-Care Molecular Diagnostic Cartridges Sales, Price, Revenue and Gross Margin (2021-2026)
11.16.5 miDiagnostics NV Recent Developments
11.17 GeneReach Biotechnology Corp.
11.17.1 GeneReach Biotechnology Corp. Corporation Information
11.17.2 GeneReach Biotechnology Corp. Business Overview
11.17.3 GeneReach Biotechnology Corp. Point-of-Care Molecular Diagnostic Cartridges Product Models, Descriptions and Specifications
11.17.4 GeneReach Biotechnology Corp. Point-of-Care Molecular Diagnostic Cartridges Sales, Price, Revenue and Gross Margin (2021-2026)
11.17.5 GeneReach Biotechnology Corp. Recent Developments
11.18 Ustar Biotechnologies Hangzhou Ltd.
11.18.1 Ustar Biotechnologies Hangzhou Ltd. Corporation Information
11.18.2 Ustar Biotechnologies Hangzhou Ltd. Business Overview
11.18.3 Ustar Biotechnologies Hangzhou Ltd. Point-of-Care Molecular Diagnostic Cartridges Product Models, Descriptions and Specifications
11.18.4 Ustar Biotechnologies Hangzhou Ltd. Point-of-Care Molecular Diagnostic Cartridges Sales, Price, Revenue and Gross Margin (2021-2026)
11.18.5 Ustar Biotechnologies Hangzhou Ltd. Recent Developments
11.19 BIONEER CORPORATION
11.19.1 BIONEER CORPORATION Corporation Information
11.19.2 BIONEER CORPORATION Business Overview
11.19.3 BIONEER CORPORATION Point-of-Care Molecular Diagnostic Cartridges Product Models, Descriptions and Specifications
11.19.4 BIONEER CORPORATION Point-of-Care Molecular Diagnostic Cartridges Sales, Price, Revenue and Gross Margin (2021-2026)
11.19.5 BIONEER CORPORATION Recent Developments
11.20 Diagnostics for the Real World Ltd.
11.20.1 Diagnostics for the Real World Ltd. Corporation Information
11.20.2 Diagnostics for the Real World Ltd. Business Overview
11.20.3 Diagnostics for the Real World Ltd. Point-of-Care Molecular Diagnostic Cartridges Product Models, Descriptions and Specifications
11.20.4 Diagnostics for the Real World Ltd. Point-of-Care Molecular Diagnostic Cartridges Sales, Price, Revenue and Gross Margin (2021-2026)
11.20.5 Diagnostics for the Real World Ltd. Recent Developments
11.21 Xi'an Tianlong Science and Technology Co., Ltd.
11.21.1 Xi'an Tianlong Science and Technology Co., Ltd. Corporation Information
11.21.2 Xi'an Tianlong Science and Technology Co., Ltd. Business Overview
11.21.3 Xi'an Tianlong Science and Technology Co., Ltd. Point-of-Care Molecular Diagnostic Cartridges Product Models, Descriptions and Specifications
11.21.4 Xi'an Tianlong Science and Technology Co., Ltd. Point-of-Care Molecular Diagnostic Cartridges Sales, Price, Revenue and Gross Margin (2021-2026)
11.21.5 Xi'an Tianlong Science and Technology Co., Ltd. Recent Developments
11.22 Baebies, Inc.
11.22.1 Baebies, Inc. Corporation Information
11.22.2 Baebies, Inc. Business Overview
11.22.3 Baebies, Inc. Point-of-Care Molecular Diagnostic Cartridges Product Models, Descriptions and Specifications
11.22.4 Baebies, Inc. Point-of-Care Molecular Diagnostic Cartridges Sales, Price, Revenue and Gross Margin (2021-2026)
11.22.5 Baebies, Inc. Recent Developments
11.23 Autonomous Medical Devices Incorporated
11.23.1 Autonomous Medical Devices Incorporated Corporation Information
11.23.2 Autonomous Medical Devices Incorporated Business Overview
11.23.3 Autonomous Medical Devices Incorporated Point-of-Care Molecular Diagnostic Cartridges Product Models, Descriptions and Specifications
11.23.4 Autonomous Medical Devices Incorporated Point-of-Care Molecular Diagnostic Cartridges Sales, Price, Revenue and Gross Margin (2021-2026)
11.23.5 Autonomous Medical Devices Incorporated Recent Developments
11.24 Nuclein, LLC
11.24.1 Nuclein, LLC Corporation Information
11.24.2 Nuclein, LLC Business Overview
11.24.3 Nuclein, LLC Point-of-Care Molecular Diagnostic Cartridges Product Models, Descriptions and Specifications
11.24.4 Nuclein, LLC Point-of-Care Molecular Diagnostic Cartridges Sales, Price, Revenue and Gross Margin (2021-2026)
11.24.5 Nuclein, LLC Recent Developments
11.25 Genedrive Diagnostics Ltd
11.25.1 Genedrive Diagnostics Ltd Corporation Information
11.25.2 Genedrive Diagnostics Ltd Business Overview
11.25.3 Genedrive Diagnostics Ltd Point-of-Care Molecular Diagnostic Cartridges Product Models, Descriptions and Specifications
11.25.4 Genedrive Diagnostics Ltd Point-of-Care Molecular Diagnostic Cartridges Sales, Price, Revenue and Gross Margin (2021-2026)
11.25.5 Genedrive Diagnostics Ltd Recent Developments
11.26 Igenesis Shanghai Co., Ltd.
11.26.1 Igenesis Shanghai Co., Ltd. Corporation Information
11.26.2 Igenesis Shanghai Co., Ltd. Business Overview
11.26.3 Igenesis Shanghai Co., Ltd. Point-of-Care Molecular Diagnostic Cartridges Product Models, Descriptions and Specifications
11.26.4 Igenesis Shanghai Co., Ltd. Point-of-Care Molecular Diagnostic Cartridges Sales, Price, Revenue and Gross Margin (2021-2026)
11.26.5 Igenesis Shanghai Co., Ltd. Recent Developments
11.27 Guangzhou Pluslife Biotech Co., Ltd.
11.27.1 Guangzhou Pluslife Biotech Co., Ltd. Corporation Information
11.27.2 Guangzhou Pluslife Biotech Co., Ltd. Business Overview
11.27.3 Guangzhou Pluslife Biotech Co., Ltd. Point-of-Care Molecular Diagnostic Cartridges Product Models, Descriptions and Specifications
11.27.4 Guangzhou Pluslife Biotech Co., Ltd. Point-of-Care Molecular Diagnostic Cartridges Sales, Price, Revenue and Gross Margin (2021-2026)
11.27.5 Guangzhou Pluslife Biotech Co., Ltd. Recent Developments

12 Value Chain and Supply-Chain Analysis
12.1 Point-of-Care Molecular Diagnostic Cartridges Industry Chain
12.2 Point-of-Care Molecular Diagnostic Cartridges Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Point-of-Care Molecular Diagnostic Cartridges Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2021-2032)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Point-of-Care Molecular Diagnostic Cartridges Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors

13 Point-of-Care Molecular Diagnostic Cartridges Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
13.4 Impact of U.S. Tariffs

14 Key Findings in the Global Point-of-Care Molecular Diagnostic Cartridges Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global Point-of-Care Molecular Diagnostic Cartridges Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Point-of-Care Molecular Diagnostic Cartridges Market Size Growth Rate by Analyte Multiplexing Level, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Point-of-Care Molecular Diagnostic Cartridges Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Point-of-Care Molecular Diagnostic Cartridges Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Point-of-Care Molecular Diagnostic Cartridges Revenue by Region (US$ Million), 2021-2026
Table 6. Global Point-of-Care Molecular Diagnostic Cartridges Revenue by Region (US$ Million), 2027-2032
Table 7. Global Point-of-Care Molecular Diagnostic Cartridges Sales Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (Units)
Table 8. Global Point-of-Care Molecular Diagnostic Cartridges Sales by Region (Units), 2021-2026
Table 9. Global Point-of-Care Molecular Diagnostic Cartridges Sales by Region (Units), 2027-2032
Table 10. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 11. Global Point-of-Care Molecular Diagnostic Cartridges Sales by Manufacturers (Units), 2021-2026
Table 12. Global Point-of-Care Molecular Diagnostic Cartridges Sales Share by Manufacturers (2021-2026)
Table 13. Global Point-of-Care Molecular Diagnostic Cartridges Revenue by Manufacturers (US$ Million), 2021-2026
Table 14. Global Point-of-Care Molecular Diagnostic Cartridges Revenue-Based Market Share by Manufacturers (2021-2026)
Table 15. Global Key Manufacturers’Ranking Shift (2024 vs. 2025) (Based on Revenue)
Table 16. Global Manufacturer by Tier (Tier 1, Tier 2, and Tier 3), based on Point-of-Care Molecular Diagnostic Cartridges Revenue, 2025
Table 17. Global Point-of-Care Molecular Diagnostic Cartridges Average Gross Margin (%) by Manufacturer (2021 vs 2025)
Table 18. Global Point-of-Care Molecular Diagnostic Cartridges Average Selling Price (ASP) by Manufacturers (US$/Unit), 2021-2026
Table 19. Key Manufacturers Point-of-Care Molecular Diagnostic Cartridges Manufacturing Base and Headquarters
Table 20. Global Point-of-Care Molecular Diagnostic Cartridges Market Concentration Ratio (CR5)
Table 21. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 22. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 23. Global Point-of-Care Molecular Diagnostic Cartridges Sales Volume by Type (Units), 2021-2026
Table 24. Global Point-of-Care Molecular Diagnostic Cartridges Sales Volume by Type (Units), 2027-2032
Table 25. Global Point-of-Care Molecular Diagnostic Cartridges Revenue by Type (US$ Million), 2021-2026
Table 26. Global Point-of-Care Molecular Diagnostic Cartridges Revenue by Type (US$ Million), 2027-2032
Table 27. Global Point-of-Care Molecular Diagnostic Cartridges Sales Volume by Analyte Multiplexing Level (Units), 2021-2026
Table 28. Global Point-of-Care Molecular Diagnostic Cartridges Sales Volume by Analyte Multiplexing Level (Units), 2027-2032
Table 29. Global Point-of-Care Molecular Diagnostic Cartridges Revenue by Analyte Multiplexing Level (US$ Million), 2021-2026
Table 30. Global Point-of-Care Molecular Diagnostic Cartridges Revenue by Analyte Multiplexing Level (US$ Million), 2027-2032
Table 31. Technical Specifications by Key Product Type
Table 32. Global Point-of-Care Molecular Diagnostic Cartridges Sales by Application (Units), 2021-2026
Table 33. Global Point-of-Care Molecular Diagnostic Cartridges Sales by Application (Units), 2027-2032
Table 34. Point-of-Care Molecular Diagnostic Cartridges High-Growth Sectors Demand CAGR (2026-2032)
Table 35. Global Point-of-Care Molecular Diagnostic Cartridges Revenue by Application (US$ Million), 2021-2026
Table 36. Global Point-of-Care Molecular Diagnostic Cartridges Revenue by Application (US$ Million), 2027-2032
Table 37. Top Customers by Region
Table 38. Top Customers by Application
Table 39. North America Point-of-Care Molecular Diagnostic Cartridges Growth Accelerators and Market Barriers
Table 40. North America Point-of-Care Molecular Diagnostic Cartridges Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 41. North America Point-of-Care Molecular Diagnostic Cartridges Sales (Units) by Country (2021 vs 2025 vs 2032)
Table 42. Europe Point-of-Care Molecular Diagnostic Cartridges Growth Accelerators and Market Barriers
Table 43. Europe Point-of-Care Molecular Diagnostic Cartridges Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 44. Europe Point-of-Care Molecular Diagnostic Cartridges Sales (Units) by Country (2021 vs 2025 vs 2032)
Table 45. Asia-Pacific Point-of-Care Molecular Diagnostic Cartridges Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Asia-Pacific Point-of-Care Molecular Diagnostic Cartridges Sales (Units) by Country (2021 vs 2025 vs 2032)
Table 47. Asia-Pacific Point-of-Care Molecular Diagnostic Cartridges Growth Accelerators and Market Barriers
Table 48. Southeast Asia Point-of-Care Molecular Diagnostic Cartridges Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 49. Central and South America Point-of-Care Molecular Diagnostic Cartridges Investment Opportunities and Key Challenges
Table 50. Central and South America Point-of-Care Molecular Diagnostic Cartridges Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 51. Middle East and Africa Point-of-Care Molecular Diagnostic Cartridges Investment Opportunities and Key Challenges
Table 52. Middle East and Africa Point-of-Care Molecular Diagnostic Cartridges Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 53. Cepheid Corporation Information
Table 54. Cepheid Description and Major Businesses
Table 55. Cepheid Product Models, Descriptions and Specifications
Table 56. Cepheid Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 57. Cepheid Sales Value Proportion by Product in 2025
Table 58. Cepheid Sales Value Proportion by Application in 2025
Table 59. Cepheid Sales Value Proportion by Geographic Area in 2025
Table 60. Cepheid Point-of-Care Molecular Diagnostic Cartridges SWOT Analysis
Table 61. Cepheid Recent Developments
Table 62. Roche Molecular Systems, Inc. Corporation Information
Table 63. Roche Molecular Systems, Inc. Description and Major Businesses
Table 64. Roche Molecular Systems, Inc. Product Models, Descriptions and Specifications
Table 65. Roche Molecular Systems, Inc. Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 66. Roche Molecular Systems, Inc. Sales Value Proportion by Product in 2025
Table 67. Roche Molecular Systems, Inc. Sales Value Proportion by Application in 2025
Table 68. Roche Molecular Systems, Inc. Sales Value Proportion by Geographic Area in 2025
Table 69. Roche Molecular Systems, Inc. Point-of-Care Molecular Diagnostic Cartridges SWOT Analysis
Table 70. Roche Molecular Systems, Inc. Recent Developments
Table 71. BioFire Diagnostics, LLC Corporation Information
Table 72. BioFire Diagnostics, LLC Description and Major Businesses
Table 73. BioFire Diagnostics, LLC Product Models, Descriptions and Specifications
Table 74. BioFire Diagnostics, LLC Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 75. BioFire Diagnostics, LLC Sales Value Proportion by Product in 2025
Table 76. BioFire Diagnostics, LLC Sales Value Proportion by Application in 2025
Table 77. BioFire Diagnostics, LLC Sales Value Proportion by Geographic Area in 2025
Table 78. BioFire Diagnostics, LLC Point-of-Care Molecular Diagnostic Cartridges SWOT Analysis
Table 79. BioFire Diagnostics, LLC Recent Developments
Table 80. Abbott Diagnostics Scarborough, Inc. Corporation Information
Table 81. Abbott Diagnostics Scarborough, Inc. Description and Major Businesses
Table 82. Abbott Diagnostics Scarborough, Inc. Product Models, Descriptions and Specifications
Table 83. Abbott Diagnostics Scarborough, Inc. Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 84. Abbott Diagnostics Scarborough, Inc. Sales Value Proportion by Product in 2025
Table 85. Abbott Diagnostics Scarborough, Inc. Sales Value Proportion by Application in 2025
Table 86. Abbott Diagnostics Scarborough, Inc. Sales Value Proportion by Geographic Area in 2025
Table 87. Abbott Diagnostics Scarborough, Inc. Point-of-Care Molecular Diagnostic Cartridges SWOT Analysis
Table 88. Abbott Diagnostics Scarborough, Inc. Recent Developments
Table 89. LEX Diagnostics Limited Corporation Information
Table 90. LEX Diagnostics Limited Description and Major Businesses
Table 91. LEX Diagnostics Limited Product Models, Descriptions and Specifications
Table 92. LEX Diagnostics Limited Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 93. LEX Diagnostics Limited Sales Value Proportion by Product in 2025
Table 94. LEX Diagnostics Limited Sales Value Proportion by Application in 2025
Table 95. LEX Diagnostics Limited Sales Value Proportion by Geographic Area in 2025
Table 96. LEX Diagnostics Limited Point-of-Care Molecular Diagnostic Cartridges SWOT Analysis
Table 97. LEX Diagnostics Limited Recent Developments
Table 98. DiaSorin Molecular LLC Corporation Information
Table 99. DiaSorin Molecular LLC Description and Major Businesses
Table 100. DiaSorin Molecular LLC Product Models, Descriptions and Specifications
Table 101. DiaSorin Molecular LLC Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 102. DiaSorin Molecular LLC Recent Developments
Table 103. Bosch Healthcare Solutions GmbH Corporation Information
Table 104. Bosch Healthcare Solutions GmbH Description and Major Businesses
Table 105. Bosch Healthcare Solutions GmbH Product Models, Descriptions and Specifications
Table 106. Bosch Healthcare Solutions GmbH Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 107. Bosch Healthcare Solutions GmbH Recent Developments
Table 108. SD BIOSENSOR, Inc. Corporation Information
Table 109. SD BIOSENSOR, Inc. Description and Major Businesses
Table 110. SD BIOSENSOR, Inc. Product Models, Descriptions and Specifications
Table 111. SD BIOSENSOR, Inc. Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 112. SD BIOSENSOR, Inc. Recent Developments
Table 113. Guangzhou Wondfo Biotech Co., Ltd. Corporation Information
Table 114. Guangzhou Wondfo Biotech Co., Ltd. Description and Major Businesses
Table 115. Guangzhou Wondfo Biotech Co., Ltd. Product Models, Descriptions and Specifications
Table 116. Guangzhou Wondfo Biotech Co., Ltd. Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 117. Guangzhou Wondfo Biotech Co., Ltd. Recent Developments
Table 118. Sansure Biotech Inc. Corporation Information
Table 119. Sansure Biotech Inc. Description and Major Businesses
Table 120. Sansure Biotech Inc. Product Models, Descriptions and Specifications
Table 121. Sansure Biotech Inc. Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 122. Sansure Biotech Inc. Recent Developments
Table 123. Molbio Diagnostics Limited Corporation Information
Table 124. Molbio Diagnostics Limited Description and Major Businesses
Table 125. Molbio Diagnostics Limited Product Models, Descriptions and Specifications
Table 126. Molbio Diagnostics Limited Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 127. Molbio Diagnostics Limited Recent Developments
Table 128. MIZUHO MEDY Co., Ltd. Corporation Information
Table 129. MIZUHO MEDY Co., Ltd. Description and Major Businesses
Table 130. MIZUHO MEDY Co., Ltd. Product Models, Descriptions and Specifications
Table 131. MIZUHO MEDY Co., Ltd. Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 132. MIZUHO MEDY Co., Ltd. Recent Developments
Table 133. Coyote Bioscience Co., Ltd. Corporation Information
Table 134. Coyote Bioscience Co., Ltd. Description and Major Businesses
Table 135. Coyote Bioscience Co., Ltd. Product Models, Descriptions and Specifications
Table 136. Coyote Bioscience Co., Ltd. Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 137. Coyote Bioscience Co., Ltd. Recent Developments
Table 138. Rocgene Beijing Scientific Instruments Co., Ltd. Corporation Information
Table 139. Rocgene Beijing Scientific Instruments Co., Ltd. Description and Major Businesses
Table 140. Rocgene Beijing Scientific Instruments Co., Ltd. Product Models, Descriptions and Specifications
Table 141. Rocgene Beijing Scientific Instruments Co., Ltd. Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 142. Rocgene Beijing Scientific Instruments Co., Ltd. Recent Developments
Table 143. Credo Diagnostics Biomedical Pte. Ltd. Corporation Information
Table 144. Credo Diagnostics Biomedical Pte. Ltd. Description and Major Businesses
Table 145. Credo Diagnostics Biomedical Pte. Ltd. Product Models, Descriptions and Specifications
Table 146. Credo Diagnostics Biomedical Pte. Ltd. Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 147. Credo Diagnostics Biomedical Pte. Ltd. Recent Developments
Table 148. miDiagnostics NV Corporation Information
Table 149. miDiagnostics NV Description and Major Businesses
Table 150. miDiagnostics NV Product Models, Descriptions and Specifications
Table 151. miDiagnostics NV Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 152. miDiagnostics NV Recent Developments
Table 153. GeneReach Biotechnology Corp. Corporation Information
Table 154. GeneReach Biotechnology Corp. Description and Major Businesses
Table 155. GeneReach Biotechnology Corp. Product Models, Descriptions and Specifications
Table 156. GeneReach Biotechnology Corp. Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 157. GeneReach Biotechnology Corp. Recent Developments
Table 158. Ustar Biotechnologies Hangzhou Ltd. Corporation Information
Table 159. Ustar Biotechnologies Hangzhou Ltd. Description and Major Businesses
Table 160. Ustar Biotechnologies Hangzhou Ltd. Product Models, Descriptions and Specifications
Table 161. Ustar Biotechnologies Hangzhou Ltd. Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 162. Ustar Biotechnologies Hangzhou Ltd. Recent Developments
Table 163. BIONEER CORPORATION Corporation Information
Table 164. BIONEER CORPORATION Description and Major Businesses
Table 165. BIONEER CORPORATION Product Models, Descriptions and Specifications
Table 166. BIONEER CORPORATION Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 167. BIONEER CORPORATION Recent Developments
Table 168. Diagnostics for the Real World Ltd. Corporation Information
Table 169. Diagnostics for the Real World Ltd. Description and Major Businesses
Table 170. Diagnostics for the Real World Ltd. Product Models, Descriptions and Specifications
Table 171. Diagnostics for the Real World Ltd. Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 172. Diagnostics for the Real World Ltd. Recent Developments
Table 173. Xi'an Tianlong Science and Technology Co., Ltd. Corporation Information
Table 174. Xi'an Tianlong Science and Technology Co., Ltd. Description and Major Businesses
Table 175. Xi'an Tianlong Science and Technology Co., Ltd. Product Models, Descriptions and Specifications
Table 176. Xi'an Tianlong Science and Technology Co., Ltd. Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 177. Xi'an Tianlong Science and Technology Co., Ltd. Recent Developments
Table 178. Baebies, Inc. Corporation Information
Table 179. Baebies, Inc. Description and Major Businesses
Table 180. Baebies, Inc. Product Models, Descriptions and Specifications
Table 181. Baebies, Inc. Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 182. Baebies, Inc. Recent Developments
Table 183. Autonomous Medical Devices Incorporated Corporation Information
Table 184. Autonomous Medical Devices Incorporated Description and Major Businesses
Table 185. Autonomous Medical Devices Incorporated Product Models, Descriptions and Specifications
Table 186. Autonomous Medical Devices Incorporated Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 187. Autonomous Medical Devices Incorporated Recent Developments
Table 188. Nuclein, LLC Corporation Information
Table 189. Nuclein, LLC Description and Major Businesses
Table 190. Nuclein, LLC Product Models, Descriptions and Specifications
Table 191. Nuclein, LLC Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 192. Nuclein, LLC Recent Developments
Table 193. Genedrive Diagnostics Ltd Corporation Information
Table 194. Genedrive Diagnostics Ltd Description and Major Businesses
Table 195. Genedrive Diagnostics Ltd Product Models, Descriptions and Specifications
Table 196. Genedrive Diagnostics Ltd Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 197. Genedrive Diagnostics Ltd Recent Developments
Table 198. Igenesis Shanghai Co., Ltd. Corporation Information
Table 199. Igenesis Shanghai Co., Ltd. Description and Major Businesses
Table 200. Igenesis Shanghai Co., Ltd. Product Models, Descriptions and Specifications
Table 201. Igenesis Shanghai Co., Ltd. Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 202. Igenesis Shanghai Co., Ltd. Recent Developments
Table 203. Guangzhou Pluslife Biotech Co., Ltd. Corporation Information
Table 204. Guangzhou Pluslife Biotech Co., Ltd. Description and Major Businesses
Table 205. Guangzhou Pluslife Biotech Co., Ltd. Product Models, Descriptions and Specifications
Table 206. Guangzhou Pluslife Biotech Co., Ltd. Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 207. Guangzhou Pluslife Biotech Co., Ltd. Recent Developments
Table 208. Key Raw Materials Distribution
Table 209. Raw Materials Key Suppliers
Table 210. Critical Raw Material Supplier Concentration (2025) & Risk Index
Table 211. Milestones in Production Technology Evolution
Table 212. Distributors List
Table 213. Market Trends and Market Evolution
Table 214. Market Drivers and Opportunities
Table 215. Market Challenges, Risks, and Restraints
Table 216. Research Programs/Design for This Report
Table 217. Key Data Information from Secondary Sources
Table 218. Key Data Information from Primary Sources

List of Figures
Figure 1. Point-of-Care Molecular Diagnostic Cartridges Product Picture
Figure 2. Global Point-of-Care Molecular Diagnostic Cartridges Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 3. PCR Molecular Diagnostic Cartridge Product Picture
Figure 4. Isothermal Amplification Molecular Diagnostic Cartridge Product Picture
Figure 5. Other Product Picture
Figure 6. Global Point-of-Care Molecular Diagnostic Cartridges Market Size Growth Rate by Analyte Multiplexing Level, 2021 vs 2025 vs 2032 (US$ Million)
Figure 7. Single Analyte Cartridge Product Picture
Figure 8. Multiplex Cartridge Product Picture
Figure 9. Other Product Picture
Figure 10. Global Point-of-Care Molecular Diagnostic Cartridges Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 11. Respiratory Infection Diagnosis
Figure 12. Tuberculosis Diagnosis
Figure 13. Sexually Transmitted Infection Diagnosis
Figure 14. Vaginal Infection Diagnosis
Figure 15. Maternal Perinatal Infection Screening
Figure 16. Blood Borne Viral Infection Diagnosis
Figure 17. Pharmacogenomic Therapy Guidance
Figure 18. Other
Figure 19. Point-of-Care Molecular Diagnostic Cartridges Report Years Considered
Figure 20. Global Point-of-Care Molecular Diagnostic Cartridges Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 21. Global Point-of-Care Molecular Diagnostic Cartridges Revenue (US$ Million), 2021-2032
Figure 22. Global Point-of-Care Molecular Diagnostic Cartridges Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 23. Global Point-of-Care Molecular Diagnostic Cartridges Revenue-Based Market Share by Region (2021-2032)
Figure 24. Global Point-of-Care Molecular Diagnostic Cartridges Sales (Units), 2021-2032
Figure 25. Global Point-of-Care Molecular Diagnostic Cartridges Sales (CAGR) by Region: 2021 vs 2025 vs 2032 (Units)
Figure 26. Global Point-of-Care Molecular Diagnostic Cartridges Sales Market Share by Region (2021-2032)
Figure 27. Top 5 and Top 10 Manufacturers Point-of-Care Molecular Diagnostic Cartridges Sales Volume Market Share in 2025
Figure 28. Global Point-of-Care Molecular Diagnostic Cartridges Revenue-Based Market Share Ranking (2025)
Figure 29. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 30. PCR Molecular Diagnostic Cartridge Revenue-Based Market Share by Manufacturer in 2025
Figure 31. Isothermal Amplification Molecular Diagnostic Cartridge Revenue-Based Market Share by Manufacturer in 2025
Figure 32. Other Revenue-Based Market Share by Manufacturer in 2025
Figure 33. Global Point-of-Care Molecular Diagnostic Cartridges Sales Volume-Based Market Share by Type (2021-2032)
Figure 34. Global Point-of-Care Molecular Diagnostic Cartridges Revenue-Based Market Share by Type (2021-2032)
Figure 35. Global Point-of-Care Molecular Diagnostic Cartridges ASP by Type (US$/Unit), 2021-2032
Figure 36. Global Point-of-Care Molecular Diagnostic Cartridges Sales Volume-Based Market Share by Analyte Multiplexing Level (2021-2032)
Figure 37. Global Point-of-Care Molecular Diagnostic Cartridges Revenue-Based Market Share by Analyte Multiplexing Level (2021-2032)
Figure 38. Global Point-of-Care Molecular Diagnostic Cartridges ASP by Analyte Multiplexing Level (US$/Unit), 2021-2032
Figure 39. Global Point-of-Care Molecular Diagnostic Cartridges Revenue-Based Market Share (2021-2032)
Figure 40. Global Point-of-Care Molecular Diagnostic Cartridges Sales Market Share by Application (2021-2032)
Figure 41. Global Point-of-Care Molecular Diagnostic Cartridges Revenue-Based Market Share by Application (2021-2032)
Figure 42. Global Point-of-Care Molecular Diagnostic Cartridges ASP by Application (US$/Unit), 2021-2032
Figure 43. North America Point-of-Care Molecular Diagnostic Cartridges Sales YoY (Units), 2021-2032
Figure 44. North America Point-of-Care Molecular Diagnostic Cartridges Revenue YoY (US$ Million), 2021-2032
Figure 45. North America Top 5 Manufacturers Point-of-Care Molecular Diagnostic Cartridges Sales Revenue (US$ Million) in 2025
Figure 46. North America Point-of-Care Molecular Diagnostic Cartridges Sales Volume (Units) by Application (2021-2032)
Figure 47. North America Point-of-Care Molecular Diagnostic Cartridges Sales Revenue (US$ Million) by Application (2021-2032)
Figure 48. US Point-of-Care Molecular Diagnostic Cartridges Revenue (US$ Million), 2021-2032
Figure 49. Canada Point-of-Care Molecular Diagnostic Cartridges Revenue (US$ Million), 2021-2032
Figure 50. Mexico Point-of-Care Molecular Diagnostic Cartridges Revenue (US$ Million), 2021-2032
Figure 51. Europe Point-of-Care Molecular Diagnostic Cartridges Sales YoY (Units), 2021-2032
Figure 52. Europe Point-of-Care Molecular Diagnostic Cartridges Revenue YoY (US$ Million), 2021-2032
Figure 53. Europe Top 5 Manufacturers Point-of-Care Molecular Diagnostic Cartridges Sales Revenue (US$ Million) in 2025
Figure 54. Europe Point-of-Care Molecular Diagnostic Cartridges Sales Volume (Units) by Application (2021-2032)
Figure 55. Europe Point-of-Care Molecular Diagnostic Cartridges Sales Revenue (US$ Million) by Application (2021-2032)
Figure 56. Germany Point-of-Care Molecular Diagnostic Cartridges Revenue (US$ Million), 2021-2032
Figure 57. France Point-of-Care Molecular Diagnostic Cartridges Revenue (US$ Million), 2021-2032
Figure 58. U.K. Point-of-Care Molecular Diagnostic Cartridges Revenue (US$ Million), 2021-2032
Figure 59. Italy Point-of-Care Molecular Diagnostic Cartridges Revenue (US$ Million), 2021-2032
Figure 60. Russia Point-of-Care Molecular Diagnostic Cartridges Revenue (US$ Million), 2021-2032
Figure 61. Asia-Pacific Point-of-Care Molecular Diagnostic Cartridges Sales YoY (Units), 2021-2032
Figure 62. Asia-Pacific Point-of-Care Molecular Diagnostic Cartridges Revenue YoY (US$ Million), 2021-2032
Figure 63. Asia-Pacific Top 8 Manufacturers Point-of-Care Molecular Diagnostic Cartridges Sales Revenue (US$ Million) in 2025
Figure 64. Asia-Pacific Point-of-Care Molecular Diagnostic Cartridges Sales Volume (Units) by Application (2021-2032)
Figure 65. Asia-Pacific Point-of-Care Molecular Diagnostic Cartridges Sales Revenue (US$ Million) by Application (2021-2032)
Figure 66. Indonesia Point-of-Care Molecular Diagnostic Cartridges Revenue (US$ Million), 2021-2032
Figure 67. Japan Point-of-Care Molecular Diagnostic Cartridges Revenue (US$ Million), 2021-2032
Figure 68. South Korea Point-of-Care Molecular Diagnostic Cartridges Revenue (US$ Million), 2021-2032
Figure 69. China Taiwan Point-of-Care Molecular Diagnostic Cartridges Revenue (US$ Million), 2021-2032
Figure 70. India Point-of-Care Molecular Diagnostic Cartridges Revenue (US$ Million), 2021-2032
Figure 71. Central and South America Point-of-Care Molecular Diagnostic Cartridges Sales YoY (Units), 2021-2032
Figure 72. Central and South America Point-of-Care Molecular Diagnostic Cartridges Revenue YoY (US$ Million), 2021-2032
Figure 73. Central and South America Top 5 Manufacturers Point-of-Care Molecular Diagnostic Cartridges Sales Revenue (US$ Million) in 2025
Figure 74. Central and South America Point-of-Care Molecular Diagnostic Cartridges Sales Volume (Units) by Application (2021-2032)
Figure 75. Central and South America Point-of-Care Molecular Diagnostic Cartridges Sales Revenue (US$ Million) by Application (2021-2032)
Figure 76. Brazil Point-of-Care Molecular Diagnostic Cartridges Revenue (US$ Million), 2021-2032
Figure 77. Argentina Point-of-Care Molecular Diagnostic Cartridges Revenue (US$ Million), 2021-2032
Figure 78. Middle East, and Africa Point-of-Care Molecular Diagnostic Cartridges Sales YoY (Units), 2021-2032
Figure 79. Middle East and Africa Point-of-Care Molecular Diagnostic Cartridges Revenue YoY (US$ Million), 2021-2032
Figure 80. Middle East and Africa Top 5 Manufacturers Point-of-Care Molecular Diagnostic Cartridges Sales Revenue (US$ Million) in 2025
Figure 81. Middle East and Africa Point-of-Care Molecular Diagnostic Cartridges Sales Volume (Units) by Application (2021-2032)
Figure 82. Middle East and Africa Point-of-Care Molecular Diagnostic Cartridges Sales Revenue (US$ Million) by Application (2021-2032)
Figure 83. GCC Countries Point-of-Care Molecular Diagnostic Cartridges Revenue (US$ Million), 2021-2032
Figure 84. Turkey Point-of-Care Molecular Diagnostic Cartridges Revenue (US$ Million), 2021-2032
Figure 85. Egypt Point-of-Care Molecular Diagnostic Cartridges Revenue (US$ Million), 2021-2032
Figure 86. South Africa Point-of-Care Molecular Diagnostic Cartridges Revenue (US$ Million), 2021-2032
Figure 87. Point-of-Care Molecular Diagnostic Cartridges Industry Chain Mapping
Figure 88. Regional Point-of-Care Molecular Diagnostic Cartridges Manufacturing Base Distribution (%)
Figure 89. Global Point-of-Care Molecular Diagnostic Cartridges Production Market Share by Region (2021-2032)
Figure 90. Point-of-Care Molecular Diagnostic Cartridges Production Process
Figure 91. Regional Point-of-Care Molecular Diagnostic Cartridges Production Cost Structure
Figure 92. Channels of Distribution (Direct Vs Distribution)
Figure 93. Bottom-up and Top-down Approaches for This Report
Figure 94. Data Triangulation
Figure 95. Key Executives Interviewed